Menu

Blog

Page 7856

Jan 2, 2020

What does it take for a psychedelic drug to get to market?

Posted by in category: biotech/medical

Any FDA-approved drug must first pass through three phases of development, to show safety and efficacy. At our launch party, Dr. Cole Marta, a principal investigator at the Multidisciplinary Association for Psychedelic Studies (MAPS) Los Angeles MDMA phase 3 study site, explains the process of drug development and what happens after a drug gets to market, including factors such as cost to the patient and insurance coverage. How would *you* like to see psychedelic medicines legally come to market?

Jan 2, 2020

Researchers build a particle accelerator that fits on a chip

Posted by in categories: biotech/medical, chemistry, computing, nanotechnology

The accelerator-on-a-chip demonstrated in Science is just a prototype, but Vuckovic said its design and fabrication techniques can be scaled up to deliver particle beams accelerated enough to perform cutting-edge experiments in chemistry, materials science and biological discovery that don’t require the power of a massive accelerator.

“The largest accelerators are like powerful telescopes. There are only a few in the world and scientists must come to places like SLAC to use them,” Vuckovic said. “We want to miniaturize accelerator technology in a way that makes it a more accessible research tool.”

Team members liken their approach to the way that computing evolved from the mainframe to the smaller but still useful PC. Accelerator-on-a-chip technology could also lead to new cancer radiation therapies, said physicist Robert Byer, a co-author of the Science paper. Again, it’s a matter of size.

Continue reading “Researchers build a particle accelerator that fits on a chip” »

Jan 2, 2020

Finding the root of consciousness: Is this brain cell your ‘mind’s eye’?

Posted by in category: neuroscience

Researchers believe they have identified specific neurons that are responsible for conscious awareness. Previous studies have implicated both thalamocortical circuits and cortico-cortico circuits in consciousness. The new study reports these networks intersect via L5p neurons. Directly activating L5p neurons made mice react to weaker sensory stimuli. The researchers say if consciousness requires L5p neurons, all brain activity without them must be unconscious.

Jan 2, 2020

Remote connections? Detangling entanglement in quantum physics

Posted by in categories: computing, encryption, quantum physics

Quantum computers, quantum cryptography and quantum (insert name here) are often in the news these days. Articles about them inevitably refer to entanglement, a property of quantum physics that makes all these magical devices possible.

Einstein called entanglement “spooky action at a distance,” a name that has stuck and become increasingly popular. Beyond just building better quantum computers, understanding and harnessing entanglement is also useful in other ways.

Continue reading “Remote connections? Detangling entanglement in quantum physics” »

Jan 2, 2020

Moon Phases 2020

Posted by in category: space

🌖 What will the Moon look like throughout 2020? Using data from our Lunar Reconnaissance Orbiter to visualize with unprecedented fidelity, NASA Goddard’s Dial-a-Moon shows you the Moon each hour: https://go.nasa.gov/37sKofB

Watch a full year of Moon phases from the Northern Hemisphere: https://go.nasa.gov/2udsqPY

From the Southern Hemisphere: https://go.nasa.gov/2QHYt1U

Jan 2, 2020

Some learning is a whole-brain affair, study shows

Posted by in categories: biotech/medical, food, neuroscience

Researchers at Johns Hopkins Medicine have successfully used a laser-assisted imaging tool to “see” what happens in brain cells of mice learning to reach out and grab a pellet of food. Their experiments, they say, add to evidence that such motor-based learning can occur in multiple areas of the brain, even ones not typically associated with motor control.

“Scientists should be looking at the entire brain to understand specific types of learning,” says Richard Huganir, Ph.D., Bloomberg Distinguished Professor and Director of the Solomon H. Snyder Department of Neuroscience at the Johns Hopkins University School of Medicine. “Different parts of the brain contribute to learning in different ways, and studying brain cell receptors can help us decipher how this works.”

The work, say the researchers, may ultimately inform efforts to develop treatments for learning-based and neurocognitive disorders.

Jan 2, 2020

Neuroscientists Discover New Kind of Signal in the Human Brain

Posted by in categories: computing, neuroscience

Scientists have uncovered a new kind of electrical process in the human brain that could play a key role in the unique way our brains compute.

Our brains are computers that work using a system of connected brain cells, called neurons, that exchange information using chemical and electric signals called action potentials. Researchers have discovered that certain cells in the human cortex, the outer layer of the brain, transmit signals in a way not seen in corresponding rodent cells. This process might be important to better understanding our unique brains and to improving programs that are based on a model of the human brain.

Jan 2, 2020

Study reveals what causes type 2 diabetes and how to reverse it

Posted by in categories: biotech/medical, innovation

Breakthrough research shows that type 2 diabetes occurs when fat from the liver overspills into the pancreas and confirms that weight loss can reverse it.

Jan 2, 2020

Novel dementia vaccine on track for human trials within two years

Posted by in categories: bioengineering, biotech/medical, neuroscience

A newly published study has described the successful results in mice of a novel vaccine designed to prevent neurodegeneration associated with Alzheimer’s disease. The researchers suggest this “dementia vaccine” is now ready for human trials, and if successful could become the “breakthrough of the next decade.”

The new study, led by the Institute for Molecular Medicine and University of California, Irvine, describes the effect of a vaccine designed to generate antibodies that both prevent, and remove, the aggregation of amyloid and tau proteins in the brain. The accumulation of these two proteins is thought to be the primary pathological cause of neurodegeneration associated with Alzheimer’s disease.

The research revealed the vaccine led to significant decreases in both tau and amyloid accumulation in the brains of bigenic mice engineered to exhibit aggregations of these toxic proteins. Many prior failed Alzheimer’s treatments over the past few years have focused individually on either amyloid or tau protein reductions, but growing evidence suggests a synergistic relationship between the two toxic proteins may be driving neurodegeneration. Hence the hypothesis a combination therapy may be the most effective way to prevent this kind of dementia.

Jan 2, 2020

BWX Technologies, Inc. | People Strong, Innovation Driven

Posted by in categories: government, nuclear energy

NUCLEAR THERMAL PROPULSION


BWX Technologies, Inc. is a leading supplier of nuclear components and fuel to the U.S. government, also providing components and services to the commercial nuclear power industry.